Narayana Hrudayalaya Ltd. announced its Q4 FY25 and FY25 results on May 23, 2025.
Q4 FY25 Consolidated operating revenue stood at ₹ 14,754 Mns, a YoY growth of 18.4%, with EBITDA of ₹ 3,846 Mns, a YoY growth of 22.2%.
FY25 Consolidated operating revenue was ₹ 54,830 Mns, a YoY growth of 12.1%, with EBITDA of ₹ 13,684 Mns, a YoY growth of 11.9%.
India revenue for Q4 FY25 was ₹ 11,088 Mns (YoY growth of 10.7%) and for FY25 was ₹ 43,499 Mns (YoY growth of 11.3%).
Cayman revenue for Q4 FY25 reached ₹ 3,797 Mns (YoY growth of 50.2%) and for FY25 was ₹ 11,829 Mns (YoY growth of 15.3%).
Consolidated PAT for Q4 FY25 was ₹ 1,962 Mns and for FY25 was ₹ 7,898 Mns.
As of March 31, 2025, net debt stood at ₹ 5,330 Mns.
Other highlights include:
1200+ Robot-Assisted Surgical procedures in FY25
332 Robotic Cardiac Surgeries in FY25
380+ Robotic Procedures in Q4 FY25
Narayana Health SRCC Children’s Hospital, Mumbai, completed 100 Epilepsy Surgeries.
MMI Narayana Hospital, Raipur, treated 3000+ patients in Radiation Oncology in Q4 FY25.
Management Commentary: Dr. Emmanuel Rupert, MD and Group CEO, stated that the financial year demonstrated strong performance across domestic and international units, reporting the highest-ever revenues and profitability margins. He highlighted the significant growth in Southern Peripheral and North units, the contribution of HCCI, and the traction in the new hospital in Camana Bay. He also mentioned the positive progress of the Integrated Care business.